Summary of Clinical Use

Piracetam is approved in the UK for the treatment of myoclonus, in combination with other anti-myoclonic therapies. It is authorised for clinical use in other European nations, and Asian and South American countries, but is not approved by the US FDA.

Mechanism Of Action and Pharmacodynamic Effects

Piracetam is a weak positive allosteric modulator of the AMPA receptor, but this may not be its primary mechanism of action, nor convey its clinical effects.

External links

For extended ADME data see the following: Electronic Medicines Compendium (eMC)